tirzepatide bone density GIP and GLP-2 together improve turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment Tirzepatide: A Promising Drug for

50,51 The initial dosing regimen of tirzepatide is 2.5 mg weekly, with the dose increased to up to 15 mg weekly usually after one month at the previous dose

Some people use lower doses during breaks rather than complete discontinuation, but this strategy lacks clinical validation

Stopping a high dose abruptly can cause rebound hunger, rapid weight regain, and blood sugar instability

High tech treatments such as radiofrequency, ultrasound, and laser can assist skin tightening by stimulating collagen generation

On the other hand the GLP1R in both cardiomyocytes and sinoatrial node cells can activate cyclic AMP (cAMP)-dependent signaling pathways